5-[3-(4-Benzyl-piperidin-1-yl)-propylsulfanyl]-[1,3,4]thiadiazol-2-ylamine

ID: ALA150403

PubChem CID: 12045495

Max Phase: Preclinical

Molecular Formula: C17H24N4S2

Molecular Weight: 348.54

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  Nc1nnc(SCCCN2CCC(Cc3ccccc3)CC2)s1

Standard InChI:  InChI=1S/C17H24N4S2/c18-16-19-20-17(23-16)22-12-4-9-21-10-7-15(8-11-21)13-14-5-2-1-3-6-14/h1-3,5-6,15H,4,7-13H2,(H2,18,19)

Standard InChI Key:  CNDAXLGGGKGYAE-UHFFFAOYSA-N

Molfile:  

     RDKit          2D

 23 25  0  0  0  0  0  0  0  0999 V2000
    9.2875   -6.5792    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    9.2000   -5.7542    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.0917   -6.7542    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.5042   -6.0375    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    9.9542   -5.4250    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.6250   -5.3417    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    8.4792   -5.3417    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   10.4292   -7.5042    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.6250   -4.5167    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.9125   -5.7542    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.4792   -4.1167    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.2000   -4.5250    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7667   -4.5292    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.3417   -5.7542    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.2000   -5.3500    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.9042   -4.1042    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.0542   -5.3417    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.7667   -5.7542    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.0542   -4.1167    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7667   -5.3625    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.3417   -4.5375    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.0542   -5.7750    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.3417   -5.3625    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  1  0
  3  1  1  0
  4  3  2  0
  5  2  2  0
  6 14  1  0
  7  2  1  0
  8  3  1  0
  9  6  1  0
 10  6  1  0
 11 12  1  0
 12 15  1  0
 13 11  1  0
 14 17  1  0
 15 10  1  0
 16  9  1  0
 17 18  1  0
 18  7  1  0
 19 13  2  0
 20 13  1  0
 21 19  1  0
 22 20  2  0
 23 22  1  0
  4  5  1  0
 16 12  1  0
 21 23  2  0
M  END

Alternative Forms

1. Parent:

   

   ALA150403

   5-[3-(4-Benzyl-piperidin-1-yl)-propylsulfanyl]-[1,3,4]thiadiazol-2-ylamine

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 348.54

Molecular Weight (Monoisotopic): 348.1442

AlogP: 3.56

#Rotatable Bonds: 7

Polar Surface Area: 55.04

Molecular Species: BASE

HBA: 6

HBD: 1

#RO5 Violations: ┄

HBA (Lipinski): 4

HBD (Lipinski): 2

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: ┄

CX Basic pKa: 8.84

CX LogP: 3.61

CX LogD: 2.15

Aromatic Rings: 2

Heavy Atoms: 23

QED Weighted: 0.61

Np Likeness Score: -1.77

References

1. Gregory TF, Wright JL, Wise LD, Meltzer LT, Serpa KA, Konkoy CS, Whittemore ER, Woodward RM..  (2000)  Parallel synthesis of a series of subtype-selective NMDA receptor antagonists.,  10  (6): [PMID:10741546] [10.1016/s0960-894x(00)00035-4]

Source

Source(1):

• Scientific Literature